thyroid binding globulin promoter Search Results


mouse igg2a  (Bio X Cell)
98
Bio X Cell mouse igg2a
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Mouse Igg2a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pm35039334-47-22-30?v=Bio+X+Cell
Average 98 stars, based on 1 article reviews
mouse igg2a - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier
begm bullet kit  (3H Biomedical)
90
3H Biomedical begm bullet kit
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Begm Bullet Kit, supplied by 3H Biomedical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pmc06784032-89-25-28?v=3H+Biomedical
Average 90 stars, based on 1 article reviews
begm bullet kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
thyroid binding globulin promoter  (Addgene inc)
94
Addgene inc thyroid binding globulin promoter
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Thyroid Binding Globulin Promoter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pm41928626-197-29-34?v=Addgene+inc
Average 94 stars, based on 1 article reviews
thyroid binding globulin promoter - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
anti rabbit igg secondary antibody  (Boster Bio)
93
Boster Bio anti rabbit igg secondary antibody
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Anti Rabbit Igg Secondary Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/10__1590_slash_1414___431x20154487-86-12-16?v=Boster+Bio
Average 93 stars, based on 1 article reviews
anti rabbit igg secondary antibody - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
gene exp abcc12 mm01241948 m1  (Thermo Fisher)
90
Thermo Fisher gene exp abcc12 mm01241948 m1
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Gene Exp Abcc12 Mm01241948 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pm33771553-693-81-80?v=Thermo+Fisher
Average 90 stars, based on 1 article reviews
gene exp abcc12 mm01241948 m1 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
begm  (Thermo Fisher)
99
Thermo Fisher begm
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Begm, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pmc06657837-32-49-34?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
begm - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
regm singlequot kit  (Lonza)
90
Lonza regm singlequot kit
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Regm Singlequot Kit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/us10752884-456-56-59?v=Lonza
Average 90 stars, based on 1 article reviews
regm singlequot kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
serum hormones (e2, fsh, prolactin, thyroid-stimulating hormone, cortisol, testosterone, and sex hormone-binding globulin)  (Srl Medisearch Inc)
90
Srl Medisearch Inc serum hormones (e2, fsh, prolactin, thyroid-stimulating hormone, cortisol, testosterone, and sex hormone-binding globulin)
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Serum Hormones (E2, Fsh, Prolactin, Thyroid Stimulating Hormone, Cortisol, Testosterone, And Sex Hormone Binding Globulin), supplied by Srl Medisearch Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pmc07659257-107-0-35?v=Srl+Medisearch+Inc
Average 90 stars, based on 1 article reviews
serum hormones (e2, fsh, prolactin, thyroid-stimulating hormone, cortisol, testosterone, and sex hormone-binding globulin) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
begm singlequots kit  (Lonza)
90
Lonza begm singlequots kit
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Begm Singlequots Kit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pmc06690249-27-34-37?v=Lonza
Average 90 stars, based on 1 article reviews
begm singlequots kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
regm complex  (Lonza)
90
Lonza regm complex
FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with <t>Rat-IgG2a,</t> anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.
Regm Complex, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thyroid+binding+globulin+promoter/pmc06405134-92-16-3?v=Lonza
Average 90 stars, based on 1 article reviews
regm complex - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tbg accubind elisa kit  (Monobind)
N/A
   Buy from Supplier

Image Search Results


FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with Rat-IgG2a, anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.

doi: 10.4049/jimmunol.2100653

Figure Lengend Snippet: FIGURE 1. Steady-state cycling of MP Tregs and CD41 MP T cells requires CD28 signaling in vivo. WT C57BL/6 mice were treated with Rat-IgG2a, anti-CD28 dAb, anti-CD80/86, CTLA4-Ig (abatacept), or anti-ICOS (250 mg/dose) on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Represen- tative plot of Ly-6C versus Ki-67 expression on splenic Tregs. (B) Percentage of Ly6C−Tregs expressing Ki-67 after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatments. (D) Representative plot of Ki-67 expression on CD41Foxp3−CD441 cells after Ab treatments. (E) Percent- age of CD41Foxp3−CD441 MP T cells expressing Ki-67. (F) Absolute number of CD41 MP T cells after Ab treatments. (G) Representative plot of Ki-67 expression on CD81 CM T cells. (H) Percentage of CD81CD62L1 T cells expressing Ki-67. (I) Absolute number of CD81 CM T cells after Ab treatments. (J) Representative plot of the percentage of CD81 EM cells expressing Ki-67. (K) Percentage of CD81 EM cells expressing Ki-67. (L) Absolute number of CD81 EM T cells after Ab treatments. (A)(L) represent the results of one experiment using two to five mice per group. ****p < 0.0001. ns, not significant.

Article Snippet: C57BL/6 mice were injected with following mAbs as indicated in the figure legends: 250 mg/dose mouse IgG1 (clone MOPC-21; Bio X Cell), mouse IgG2a (clone C1.18.4), rat IgG2a (clone 2A3; Bio X Cell), human CD28 domain-specific Ab (100 mg/dose; Bristol Myers Squibb), 250 mg/dose antiCD80 (clone 1G10; Bio X Cell), anti-CD86 (clone GL-1; Bio X Cell), CTLA4-Ig (abatacept, Bristol Myers Squibb), anti-ICOS (clone 7E.17G9; Bio X Cell), anti-CTLA4 (clone UC10-4F10-11; Bio X Cell), anti PD-1 (clone 29F.1A12; Bio X Cell), TIM-3 (clone RMT3.23; Bio X Cell), TIGIT (clone 1G9; Bio X Cell), BTLA (clone 6A6, Bio X Cell), VISTA (clone 13F3; Bio X Cell), CD70 (clone FR70; Bio X Cell), CD48 (clone HM48.1; Bio X Cell), TNF-a (clone XT3.11; Bio X Cell), IFN-g (clone XMG1.2; Bio X Cell), IFNAR (clone MAR1-5A3; Bio X Cell), IFN-g receptor (clone GR20), IL-7 (clone M25; Bio X Cell), IL-7Ra (clone A7R34; Bio X Cell), CD40 (50 mg/dose; clone FGK4.5; Bio X Cell, CD40L (clone MR-1; Bio X Cell), GITR (clone DTA-1; Bio X Cell), OX40 (clone OX-86; Bio X Cell), 4-1BB (clone LOB12.3; Bio X Cell), and anti MHC-I (500 mg/dose; clone M1/42; Bio X Cell).

Techniques: In Vivo, Expressing

FIGURE 2. CD80/CD86 signaling is critical for CD41 MP cell and Treg homeostasis in both lymphoid and nonlymphoid sites, but the effects of mAb treatment are reversible. (AH) WT C57BL/6 mice were injected with either rat IgG2a or anti-CD28 dAb every other day for 6 d, and lymphocytes from mesenteric lymph nodes (AD) and liver (E-H) were harvested on day 8. (A) Ki-67 expression on Ly-6C−. (B) Absolute number of Tregs on day 8. (C) Ki-67 expression on CD41Foxp3−CD441 T cells. (D) Absolute number of CD41Foxp3−CD441 T cells. (E) Ki-67 expression on Ly-6C−Tregs. (F) Absolute number of Tregs. (G) Ki-67 expression on CD41Foxp3−CD441 T cells. (H) Absolute number of CD41Foxp3−CD441 T cells. (IP) C57BL/6 mice were injected with rat IgG2a or anti-CD80/ CD86 on days 0, 2, 4, and 6. Splenic cells were harvested on day 30 or 45. (I and J) Percentage of CD41Foxp31 Tregs and Ki-67 expression on Ly-6C−Tregs on day 30. (K and L) Percentage of Tregs and Ki-67 expression on Ly-6C−Tregs on day 45. (M and N) Absolute number of Tregs and CD41Foxp3−CD441 T cells on day 30. (O and P) Absolute number of Treg and CD41Foxp3−CD441 T cells on day 45. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.

doi: 10.4049/jimmunol.2100653

Figure Lengend Snippet: FIGURE 2. CD80/CD86 signaling is critical for CD41 MP cell and Treg homeostasis in both lymphoid and nonlymphoid sites, but the effects of mAb treatment are reversible. (AH) WT C57BL/6 mice were injected with either rat IgG2a or anti-CD28 dAb every other day for 6 d, and lymphocytes from mesenteric lymph nodes (AD) and liver (E-H) were harvested on day 8. (A) Ki-67 expression on Ly-6C−. (B) Absolute number of Tregs on day 8. (C) Ki-67 expression on CD41Foxp3−CD441 T cells. (D) Absolute number of CD41Foxp3−CD441 T cells. (E) Ki-67 expression on Ly-6C−Tregs. (F) Absolute number of Tregs. (G) Ki-67 expression on CD41Foxp3−CD441 T cells. (H) Absolute number of CD41Foxp3−CD441 T cells. (IP) C57BL/6 mice were injected with rat IgG2a or anti-CD80/ CD86 on days 0, 2, 4, and 6. Splenic cells were harvested on day 30 or 45. (I and J) Percentage of CD41Foxp31 Tregs and Ki-67 expression on Ly-6C−Tregs on day 30. (K and L) Percentage of Tregs and Ki-67 expression on Ly-6C−Tregs on day 45. (M and N) Absolute number of Tregs and CD41Foxp3−CD441 T cells on day 30. (O and P) Absolute number of Treg and CD41Foxp3−CD441 T cells on day 45. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.

Article Snippet: C57BL/6 mice were injected with following mAbs as indicated in the figure legends: 250 mg/dose mouse IgG1 (clone MOPC-21; Bio X Cell), mouse IgG2a (clone C1.18.4), rat IgG2a (clone 2A3; Bio X Cell), human CD28 domain-specific Ab (100 mg/dose; Bristol Myers Squibb), 250 mg/dose antiCD80 (clone 1G10; Bio X Cell), anti-CD86 (clone GL-1; Bio X Cell), CTLA4-Ig (abatacept, Bristol Myers Squibb), anti-ICOS (clone 7E.17G9; Bio X Cell), anti-CTLA4 (clone UC10-4F10-11; Bio X Cell), anti PD-1 (clone 29F.1A12; Bio X Cell), TIM-3 (clone RMT3.23; Bio X Cell), TIGIT (clone 1G9; Bio X Cell), BTLA (clone 6A6, Bio X Cell), VISTA (clone 13F3; Bio X Cell), CD70 (clone FR70; Bio X Cell), CD48 (clone HM48.1; Bio X Cell), TNF-a (clone XT3.11; Bio X Cell), IFN-g (clone XMG1.2; Bio X Cell), IFNAR (clone MAR1-5A3; Bio X Cell), IFN-g receptor (clone GR20), IL-7 (clone M25; Bio X Cell), IL-7Ra (clone A7R34; Bio X Cell), CD40 (50 mg/dose; clone FGK4.5; Bio X Cell, CD40L (clone MR-1; Bio X Cell), GITR (clone DTA-1; Bio X Cell), OX40 (clone OX-86; Bio X Cell), 4-1BB (clone LOB12.3; Bio X Cell), and anti MHC-I (500 mg/dose; clone M1/42; Bio X Cell).

Techniques: Injection, Expressing

FIGURE 7. M1/42 administration enhances systemic proinflammatory cytokine production. (AC) WT C57BL/6 mice were injected with rat IgG2a or M1/42 (pan-antiMHC-I) on days 0, 2, 4, and 6. Plasma was col- lected on day 8 to measure IFN-g (A), TNF-a (B), and IL-6 (C) levels by cytometric bead array.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.

doi: 10.4049/jimmunol.2100653

Figure Lengend Snippet: FIGURE 7. M1/42 administration enhances systemic proinflammatory cytokine production. (AC) WT C57BL/6 mice were injected with rat IgG2a or M1/42 (pan-antiMHC-I) on days 0, 2, 4, and 6. Plasma was col- lected on day 8 to measure IFN-g (A), TNF-a (B), and IL-6 (C) levels by cytometric bead array.

Article Snippet: C57BL/6 mice were injected with following mAbs as indicated in the figure legends: 250 mg/dose mouse IgG1 (clone MOPC-21; Bio X Cell), mouse IgG2a (clone C1.18.4), rat IgG2a (clone 2A3; Bio X Cell), human CD28 domain-specific Ab (100 mg/dose; Bristol Myers Squibb), 250 mg/dose antiCD80 (clone 1G10; Bio X Cell), anti-CD86 (clone GL-1; Bio X Cell), CTLA4-Ig (abatacept, Bristol Myers Squibb), anti-ICOS (clone 7E.17G9; Bio X Cell), anti-CTLA4 (clone UC10-4F10-11; Bio X Cell), anti PD-1 (clone 29F.1A12; Bio X Cell), TIM-3 (clone RMT3.23; Bio X Cell), TIGIT (clone 1G9; Bio X Cell), BTLA (clone 6A6, Bio X Cell), VISTA (clone 13F3; Bio X Cell), CD70 (clone FR70; Bio X Cell), CD48 (clone HM48.1; Bio X Cell), TNF-a (clone XT3.11; Bio X Cell), IFN-g (clone XMG1.2; Bio X Cell), IFNAR (clone MAR1-5A3; Bio X Cell), IFN-g receptor (clone GR20), IL-7 (clone M25; Bio X Cell), IL-7Ra (clone A7R34; Bio X Cell), CD40 (50 mg/dose; clone FGK4.5; Bio X Cell, CD40L (clone MR-1; Bio X Cell), GITR (clone DTA-1; Bio X Cell), OX40 (clone OX-86; Bio X Cell), 4-1BB (clone LOB12.3; Bio X Cell), and anti MHC-I (500 mg/dose; clone M1/42; Bio X Cell).

Techniques: Injection, Clinical Proteomics

FIGURE 6. CD28 signaling modulates Treg and CD41 MP T cell proliferation after treatment with agonistic anti-CD40. WT C57BL/6 mice were treated with rat IgG2a, anti-CD28 dAb (100 mg/dose; i.p.), anti-CD40 (50 mg/dose; i.p.), anti-CD40L (250 mg/dose), or anti-CD40 together with anti-CD28 dAb on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Representative plots of Ly-6C versus Ki-67 expression on CD41Foxp31 Tregs. (B) Ki-67 expression on Ly6C−Tregs after Ab treatment. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatment. (D) Expression of Ki-67 on CD41Foxp3−CD441 MP T cells after Ab treatment. (E) Percentage of Ki-67 expression on CD41 MP T cells. (F) Absolute number of CD41 MP T cells after Ab treatment. (G) Representative plot of the expression of Ki-67 on CD81 CM T cells. (H) Ki-67 expression on CD81 CM T cells. (I) Absolute number of CD81 CM T cells after Ab treatment. (J) Representative plot of the expression of Ki-67 on CD81 EM T cells. (K) Ki-67 expression on CD81 EM T cells. (L) Absolute number of CD81 EM T cells after Ab treatment. (A)(L) represent the result of one experiment of two using five mice per group. **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.

doi: 10.4049/jimmunol.2100653

Figure Lengend Snippet: FIGURE 6. CD28 signaling modulates Treg and CD41 MP T cell proliferation after treatment with agonistic anti-CD40. WT C57BL/6 mice were treated with rat IgG2a, anti-CD28 dAb (100 mg/dose; i.p.), anti-CD40 (50 mg/dose; i.p.), anti-CD40L (250 mg/dose), or anti-CD40 together with anti-CD28 dAb on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Representative plots of Ly-6C versus Ki-67 expression on CD41Foxp31 Tregs. (B) Ki-67 expression on Ly6C−Tregs after Ab treatment. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatment. (D) Expression of Ki-67 on CD41Foxp3−CD441 MP T cells after Ab treatment. (E) Percentage of Ki-67 expression on CD41 MP T cells. (F) Absolute number of CD41 MP T cells after Ab treatment. (G) Representative plot of the expression of Ki-67 on CD81 CM T cells. (H) Ki-67 expression on CD81 CM T cells. (I) Absolute number of CD81 CM T cells after Ab treatment. (J) Representative plot of the expression of Ki-67 on CD81 EM T cells. (K) Ki-67 expression on CD81 EM T cells. (L) Absolute number of CD81 EM T cells after Ab treatment. (A)(L) represent the result of one experiment of two using five mice per group. **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, not significant.

Article Snippet: C57BL/6 mice were injected with following mAbs as indicated in the figure legends: 250 mg/dose mouse IgG1 (clone MOPC-21; Bio X Cell), mouse IgG2a (clone C1.18.4), rat IgG2a (clone 2A3; Bio X Cell), human CD28 domain-specific Ab (100 mg/dose; Bristol Myers Squibb), 250 mg/dose antiCD80 (clone 1G10; Bio X Cell), anti-CD86 (clone GL-1; Bio X Cell), CTLA4-Ig (abatacept, Bristol Myers Squibb), anti-ICOS (clone 7E.17G9; Bio X Cell), anti-CTLA4 (clone UC10-4F10-11; Bio X Cell), anti PD-1 (clone 29F.1A12; Bio X Cell), TIM-3 (clone RMT3.23; Bio X Cell), TIGIT (clone 1G9; Bio X Cell), BTLA (clone 6A6, Bio X Cell), VISTA (clone 13F3; Bio X Cell), CD70 (clone FR70; Bio X Cell), CD48 (clone HM48.1; Bio X Cell), TNF-a (clone XT3.11; Bio X Cell), IFN-g (clone XMG1.2; Bio X Cell), IFNAR (clone MAR1-5A3; Bio X Cell), IFN-g receptor (clone GR20), IL-7 (clone M25; Bio X Cell), IL-7Ra (clone A7R34; Bio X Cell), CD40 (50 mg/dose; clone FGK4.5; Bio X Cell, CD40L (clone MR-1; Bio X Cell), GITR (clone DTA-1; Bio X Cell), OX40 (clone OX-86; Bio X Cell), 4-1BB (clone LOB12.3; Bio X Cell), and anti MHC-I (500 mg/dose; clone M1/42; Bio X Cell).

Techniques: Expressing

FIGURE 8. CD28 signaling regulates NK celldependent enhancement of CD41 MP T cell, but not CD81 MP T cell, proliferation. C57BL/6 mice were treated with rat IgG2a, M1/42 (500 mg/dose), anti-CD80/86 (250 mg/dose), and M1/42 together with anti-CD80/86 on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Representative plots of Ly-6C versus Ki-67 expression on CD41Foxp31 splenic Tregs. (B) Expression of Ki-67 on Ly6C−Tregs after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatment. (D) Representative plots of the expression of Ki-67 on CD41Foxp3−CD441 MP T cells after Ab treatment. (E) Expression of Ki-67 on CD41 MP T cells. (F) Absolute number of CD41 MP T cells after Ab treatment. (G) Representative plots of the expression of Ki-67 on CD81 CM T cells. (H) Percentage of Ki-671CD81 CM T cells. (I) Absolute number of CD81 CM T cells after Ab treatment. (J) Representa- tive plots of Ki-67 expression on CD81 EM T cells. (K) Percentage of Ki-671CD81 CM T cells. (L) Absolute number of CD81 EM T cells after Ab treatment. (A)(L) represent the result of one experiment of two using five mice per group. ****p < 0.0001. ns, not significant.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.

doi: 10.4049/jimmunol.2100653

Figure Lengend Snippet: FIGURE 8. CD28 signaling regulates NK celldependent enhancement of CD41 MP T cell, but not CD81 MP T cell, proliferation. C57BL/6 mice were treated with rat IgG2a, M1/42 (500 mg/dose), anti-CD80/86 (250 mg/dose), and M1/42 together with anti-CD80/86 on days 0, 2, 4, and 6 and spleens were harvested on day 8. (A) Representative plots of Ly-6C versus Ki-67 expression on CD41Foxp31 splenic Tregs. (B) Expression of Ki-67 on Ly6C−Tregs after Ab treatments. (C) Absolute number of splenic CD41Foxp31 T cells after Ab treatment. (D) Representative plots of the expression of Ki-67 on CD41Foxp3−CD441 MP T cells after Ab treatment. (E) Expression of Ki-67 on CD41 MP T cells. (F) Absolute number of CD41 MP T cells after Ab treatment. (G) Representative plots of the expression of Ki-67 on CD81 CM T cells. (H) Percentage of Ki-671CD81 CM T cells. (I) Absolute number of CD81 CM T cells after Ab treatment. (J) Representa- tive plots of Ki-67 expression on CD81 EM T cells. (K) Percentage of Ki-671CD81 CM T cells. (L) Absolute number of CD81 EM T cells after Ab treatment. (A)(L) represent the result of one experiment of two using five mice per group. ****p < 0.0001. ns, not significant.

Article Snippet: C57BL/6 mice were injected with following mAbs as indicated in the figure legends: 250 mg/dose mouse IgG1 (clone MOPC-21; Bio X Cell), mouse IgG2a (clone C1.18.4), rat IgG2a (clone 2A3; Bio X Cell), human CD28 domain-specific Ab (100 mg/dose; Bristol Myers Squibb), 250 mg/dose antiCD80 (clone 1G10; Bio X Cell), anti-CD86 (clone GL-1; Bio X Cell), CTLA4-Ig (abatacept, Bristol Myers Squibb), anti-ICOS (clone 7E.17G9; Bio X Cell), anti-CTLA4 (clone UC10-4F10-11; Bio X Cell), anti PD-1 (clone 29F.1A12; Bio X Cell), TIM-3 (clone RMT3.23; Bio X Cell), TIGIT (clone 1G9; Bio X Cell), BTLA (clone 6A6, Bio X Cell), VISTA (clone 13F3; Bio X Cell), CD70 (clone FR70; Bio X Cell), CD48 (clone HM48.1; Bio X Cell), TNF-a (clone XT3.11; Bio X Cell), IFN-g (clone XMG1.2; Bio X Cell), IFNAR (clone MAR1-5A3; Bio X Cell), IFN-g receptor (clone GR20), IL-7 (clone M25; Bio X Cell), IL-7Ra (clone A7R34; Bio X Cell), CD40 (50 mg/dose; clone FGK4.5; Bio X Cell, CD40L (clone MR-1; Bio X Cell), GITR (clone DTA-1; Bio X Cell), OX40 (clone OX-86; Bio X Cell), 4-1BB (clone LOB12.3; Bio X Cell), and anti MHC-I (500 mg/dose; clone M1/42; Bio X Cell).

Techniques: Expressing